<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270802</url>
  </required_header>
  <id_info>
    <org_study_id>Merck 38258</org_study_id>
    <nct_id>NCT01270802</nct_id>
  </id_info>
  <brief_title>Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients</brief_title>
  <official_title>A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone
      problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a
      newer HIV medication, will improve vascular function and tests of bone health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) is an increasingly important comorbidity in HIV-infected
      patients. Our preliminary data suggests that efavirenz may worsen endothelial function, which
      in turn may increase the risk for future CVD events. Efavirenz has also been linked to lower
      vitamin D levels, which may in turn result in increased bone fragility. Raltegravir is not
      known to affect either endothelial function or vitamin D levels. Therefore, switching
      efavirenz to raltegravir in patients with suppressed HIV viremia may lead to improved
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow-mediated Dilation (FMD) of the Brachial Artery</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change in FMD is a measure of change in endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Levels of Vitamin D</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change in serum levels of 24-OH-vitamin D provide a measure of the amount of change in vitamin D in the body</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Tenofovir/emtricitabine/efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir/emtricitabine/efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir/emtricitabine plus raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/emtricitabine</intervention_name>
    <description>Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine</description>
    <arm_group_label>Tenofovir/emtricitabine plus raltegravir</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/emtricitabine/efavirenz</intervention_name>
    <description>Continued therapy with tenofovir/emtricitabine/efavirenz</description>
    <arm_group_label>Tenofovir/emtricitabine/efavirenz</arm_group_label>
    <other_name>Atripla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine</description>
    <arm_group_label>Tenofovir/emtricitabine plus raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
             confirmed by a licensed Western blot or a second antibody test by a method other than
             the initial rapid HIV and/or E/CIA, or (2) by two detectable HIV-1 antigens, or (3)
             two detectable plasma HIV-1 RNA viral loads.

          -  Age equal to or greater than 18 years.

          -  Receipt of TDF/FTC/EFV as the subject's initial ART regimen for at least one year
             prior to Screening.

        Note: Interruptions in TDF/FTC/EFV of up to 10 days total during the 90 days prior to
        screening are allowed.

        Note: Subjects who had received 3TC (lamivudine) with TDF/EFV as part of their initial
        regimen but have received TDF/FTC/EFV for at least one year prior to screening will be
        eligible.

          -  HIV-1 RNA level &lt;50copies/mL at screening and with a history of having an HIV-1 RNA
             level of &lt;50copies/mL between 1 and 6 months prior to screening.

          -  At least one genotypic resistance test done prior to initiation of TDF/FTC/EFV
             suggesting no evidence of antiretroviral resistance to any nucleos(t)ide reverse
             transcriptase inhibitor or non-nucleoside reverse transcriptase inhibitor.

          -  No previous use of raltegravir or other integrase inhibitor.

          -  For women of reproductive potential, a negative urine pregnancy test at screening and
             willingness to use two forms of birth control during the course of the study.
             Acceptable forms of birth control include condoms (with or without a gel that can kill
             sperm), a diaphragm or cervical cap (with or without a gel that can kill sperm), an
             intrauterine device (IUD), or hormonal-based birth control (&quot;the pill&quot;).

        Exclusion Criteria:

          -  Inability to complete written, informed consent.

          -  Incarceration at the time of any study visit.

          -  Diagnosed vascular disease (history of angina pectoris, coronary disease, peripheral
             vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known
             atherosclerotic disease).

          -  Diagnosed disease or process, besides HIV infection, associated with increased
             systemic inflammation (including, but not limited to, systemic lupus erythematosis,
             inflammatory bowel diseases, other collagen vascular diseases).

        Note: Hepatitis B or C co-infections are NOT exclusionary

          -  Known or suspected malignancy requiring systemic treatment within six months of
             screening.

          -  History of ADA-defined diabetes mellitus

        Note: History of gestational diabetes is not exclusionary if the potential subject does not
        have current ADA-defined diabetes.

          -  History of migraine headaches.

          -  History of Raynaud's phenomenon.

          -  History of cardiac arrhythmias or cardiomyopathy.

          -  Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the
             local reference range on most recent clinical assessment.

          -  History of hypoparathyroidism or hyperparathyroidism, even if treated.

          -  Known allergy or intolerance to nitroglycerin.

          -  History of carotid bruits.

          -  Creatinine clearance &lt; 50mL/min (using the Cockcroft-Gault equation) using a serum
             creatinine level measured at screening.

          -  Hemoglobin &lt; 9.0mg/dL at screening.

          -  Alanine aminotransferase (ALT) level or aspartate aminotransferase (AST) &gt; 3 times ULN
             at screening.

          -  Total bilirubin &gt; 2.5 times ULN at screening.

          -  Fever, defined as T â‰¥ 38.0C within 48 hours prior to screening.

        Note: Fever within 48 hours prior to each main study visit will require postponement of
        that study visit until the patient has defervesced (T &lt; 38.0C) for at least 48 hours;
        fevers continuing past the allowed study visit timeframe will result in study
        discontinuation.

          -  Therapy for acute infection or other serious medical illnesses within 14 days prior to
             screening.

        Note: Therapy for acute infection or other serious medical illnesses that overlaps with a
        main study visit will result in postponement of that study visit until the course of
        therapy is completed; postponement outside of the allowed study visit timeframe will result
        in study discontinuation.

          -  Pregnancy or breastfeeding during the course of the study.

          -  Hypotension, defined as systolic blood pressure &lt; 90mmHg, at time of screening.

        Note: Hypotension noted prior to brachial artery reactivity testing on each main study
        visit will result in study visit postponement of at least one day until systolic pressure
        is â‰¥ 90mmHg the morning of brachial reactivity testing; postponement outside of the allowed
        study visit timeframe will result in study discontinuation.

          -  Uncontrolled hypertension, defined as systolic blood pressure &gt; 160mmHg or diastolic
             blood pressure &gt; 100mgHg at screening.

          -  Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids
             (of any dose), or anabolic steroids at screening.

        Note: Physiologic testosterone replacement therapy is not exclusionary.

          -  Receipt of lipid-lowering drugs or anticonvulsants (defined as those drugs with
             significant CYP 450 induction or inhibition) screening.

          -  Use of sildenafil, vardenafil, or tadalafil within 72 hours (before or after) of each
             main study visit.

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>August 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2013</results_first_posted>
  <last_update_submitted>November 24, 2013</last_update_submitted>
  <last_update_submitted_qc>November 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir Gupta</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Endothelial function</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Raltegravir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment into this trial occurred between April 2011 and May 2012. Participants were recruited from the HIV outpatient clinics associated with the Indiana University Health medical system.</recruitment_details>
      <pre_assignment_details>Thirty-two persons screened for enrollment. Two of these failed screening (both for having screening HIV-1 RNA levels &gt;50 copies/mL); the remaining 30 were equally randomized into the two study groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continued Tenofovir/Emtricitabine/Efavirenz</title>
          <description>Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz (as Atripla) one pill per day</description>
        </group>
        <group group_id="P2">
          <title>Switch to Tenofovir/Emtricitabine Plus Raltegravir</title>
          <description>Tenofovir/emtricitabine/raltegravir : Tenofovir/emtricitabine/efavirenz (as Atripla one pill per day) will be switched to tenofovir/emtricitabine (as Truvada one pill per day) plus raltegravir (as Isentress) 400mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continued Tenofovir/Emtricitabine/Efavirenz</title>
          <description>Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz</description>
        </group>
        <group group_id="B2">
          <title>Switch to Tenofovir/Emtricitabine/Raltegravir</title>
          <description>Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine/raltegravir
Tenofovir/emtricitabine/raltegravir : Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="12"/>
                    <measurement group_id="B2" value="39" spread="10.6"/>
                    <measurement group_id="B3" value="39" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow-mediated Dilation (FMD) of the Brachial Artery</title>
        <description>Change in FMD is a measure of change in endothelial function</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>In the Switch to tenofovir/emtricitabine plus raltegravir arm, two FMD measurements at 24 weeks were removed from the analysis due to poor quality imaging.</population>
        <group_list>
          <group group_id="O1">
            <title>Continued Tenofovir/Emtricitabine/Efavirenz</title>
            <description>Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz</description>
          </group>
          <group group_id="O2">
            <title>Switch to Tenofovir/Emtricitabine Plus Raltegravir</title>
            <description>Tenofovir/emtricitabine plus raltegravir 400mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Dilation (FMD) of the Brachial Artery</title>
          <description>Change in FMD is a measure of change in endothelial function</description>
          <population>In the Switch to tenofovir/emtricitabine plus raltegravir arm, two FMD measurements at 24 weeks were removed from the analysis due to poor quality imaging.</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="3.35"/>
                    <measurement group_id="O2" value="-0.1" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assumed that the declines in FMD seen with TDF/FTC/EFV in our previous study would fully reverse. Thus, the clinically relevant effect size to be detected for FMD change was +3.12% (SD 4%) in those switching from EFV to RAL. Using a two-sample, independent, two-tailed t-test with 5% type I error and 20% type II error, a sample size of 13 per group would be needed to find a difference in FMD between groups. Allowing for a 10% dropout rate, we planned to recruit 15 subjects per group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; P&lt;0.05 was considered statistically significant.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Levels of Vitamin D</title>
        <description>Change in serum levels of 24-OH-vitamin D provide a measure of the amount of change in vitamin D in the body</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continued Tenofovir/Emtricitabine/Efavirenz</title>
            <description>Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz</description>
          </group>
          <group group_id="O2">
            <title>Switch to Tenofovir/Emtricitabine Plus Raltegravir</title>
            <description>Tenofovir/emtricitabine/efavirenz will be switched to tenofovir/emtricitabine plus raltegravir 400mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Levels of Vitamin D</title>
          <description>Change in serum levels of 24-OH-vitamin D provide a measure of the amount of change in vitamin D in the body</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.23"/>
                    <measurement group_id="O2" value="0.14" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. P&lt;0.05 was considered statistically significant.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.04</ci_lower_limit>
            <ci_upper_limit>9.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Laboratory toxicities were assessed at week 8 and week 24.</desc>
      <group_list>
        <group group_id="E1">
          <title>Continued Tenofovir/Emtricitabine/Efavirenz</title>
          <description>Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz</description>
        </group>
        <group group_id="E2">
          <title>Switch to Tenofovir/Emtricitabine/Raltegravir</title>
          <description>Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine/raltegravir
Tenofovir/emtricitabine/raltegravir : Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Virologic failure</sub_title>
                <description>Confirmed HIV-1 RNA over 50 copies/mL</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was open-label. Correction for multiple testing was not performed, so apparently significant results may be falsely positive.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Samir K. Gupta, Principal Investigator</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-274-7926</phone>
      <email>sgupta1@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

